Similar articles

• Pharmacovigilance: Importance, concepts, and processes.

  Kumar A. Kumar A. Am J Health Syst Pharm. 2017 Apr 15;74(8):606-612. doi: 10.2146/ajhp151031. Epub 2017 Feb 24. Am J Health Syst Pharm. 2017. PMID: 28235869 No abstract available.
• Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.

  Montastruc JL, Sommet A, Lacroix I, Olivier P, Durrieu G, Damase-Michel C, Lapeyre-Mestre M, Bagheri H. Montastruc JL, et al. Joint Bone Spine. 2006 Dec;73(6):629-32. doi: 10.1016/j.jbspin.2006.09.002. Epub 2006 Oct 12. Joint Bone Spine. 2006. PMID: 17110152 Review. No abstract available.
• Principles of signal detection in pharmacovigilance.

  Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Meyboom RH, et al. Drug Saf. 1997 Jun;16(6):355-65. doi: 10.2165/00002018-199716060-00002. Drug Saf. 1997. PMID: 9241490 Review.
• Pharmacovigilance activities in Nepal.

  Palaian S, Mohamed Ibrahim MI, Mishra P, Alam K, Shankar PR, Thapa BB. Palaian S, et al. Drug Saf. 2010 Oct 1;33(10):889-90. doi: 10.2165/11532480-000000000-00000. Drug Saf. 2010. PMID: 20812773 No abstract available.
• Updating the French method for the causality assessment of adverse drug reactions.

  Arimone Y, Bidault I, Dutertre JP, Gérardin M, Guy C, Haramburu F, Hillaire-Buys D, Meglio C, Penfornis C, Théophile H, Valnet-Rabier MB; Cercle de Réflexion sur l’Imputabilité (CRI). Arimone Y, et al. Therapie. 2013 Mar-Apr;68(2):69-76. doi: 10.2515/therapie/2013016. Epub 2013 Jun 18. Therapie. 2013. PMID: 23773347 Review.